A randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, tolerability, pharmacokinetics and clinical response of repeated subcutaneous doses of E1 in combination with G1 in patients with type 2 diabetes
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Epidermal growth factor (Primary) ; TT 223 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors OPKO Health; Transition Therapeutics
- 05 Mar 2007 Interim results have been presented (at 3-months post-treatment)
- 27 Jun 2006 New trial record.